CTS-Clinical and Translational Science

Papers
(The H4-Index of CTS-Clinical and Translational Science is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer724
Intradermal substance P as a challenge agent in healthy individuals251
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker174
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection132
91
Issue Information91
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study84
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community72
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists72
Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System71
Issue Information62
59
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine56
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications54
The Effect of Diabetes Medication on the Scores of the GNRI and CONUT Nutritional Indices: Cross‐S53
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study49
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin47
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index46
Issue Information44
Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine‐Induced Myelosuppression in Australia: A Budget Impact Analysis43
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units42
Glucocorticoid‐Induced Tumor Necrosis Factor Receptor Ligand: Correlation and Therapeutic Potential for Cognitive Impairment in Temporal Lobe Epilepsy42
Integrative Use of Ningmitai Capsule and Cefoxitin in Treating Post‐Ureteroscopic Lithotripsy Stent‐Related Urinary Tract Infections41
Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data40
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry37
Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial37
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document36
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data34
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome33
Generalizability in real‐world trials33
Simulated Y‐Site Compatibility of Calcium Gluconate and Benzylpenicillin With Maintenance Fluid Used in Neonatal Intensive Care Unit32
Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans31
0.096535921096802